Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
Ocular Therapeutix (NASDAQ: OCUL) has announced multiple presentations scheduled for the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. The presentations will focus on their key product OTX-TKI, featuring three distinct sessions:
1. Dr. Carl J. Danzig will present on OTX-TKI's progression from Phase 1 to Phase 3, discussing the SOL-1 and SOL-R trials for neovascular AMD at 2:30 PM ET.
2. Dr. Mark R. Barakat will share Phase 1 results of the intravitreal axitinib implant (OTX-TKI) for treating non-proliferative diabetic retinopathy at 5:20 PM ET.
3. Dr. Justis P. Ehlers will present volumetric macular fluid analysis findings from the HELIOS Clinical Trial at 5:25 PM ET, examining the impact of a single axitinib intravitreal implant in diabetic retinopathy treatment.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato diverse presentazioni programmate per il meeting virtuale sull'Angiogenesi, Exudazione e Degenerazione 2025 che si terrà l'8 febbraio 2025. Le presentazioni si concentreranno sul loro prodotto principale OTX-TKI, con tre sessioni distinte:
1. Il Dr. Carl J. Danzig presenterà l'avanzamento di OTX-TKI dalla Fase 1 alla Fase 3, discutendo gli studi SOL-1 e SOL-R per l'AMD neovascolare alle 14:30 ET.
2. Il Dr. Mark R. Barakat condividerà i risultati della Fase 1 dell'impianto intravitreale di axitinib (OTX-TKI) per il trattamento della retinopatia diabetica non proliferativa alle 17:20 ET.
3. Il Dr. Justis P. Ehlers presenterà i risultati dell'analisi del fluido maculare volumetrico dallo Studio Clinico HELIOS alle 17:25 ET, esaminando l'impatto di un singolo impianto intravitreale di axitinib nel trattamento della retinopatia diabetica.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado múltiples presentaciones programadas para la reunión virtual sobre Angiogénesis, Exudación y Degeneración 2025 el 8 de febrero de 2025. Las presentaciones se centrará en su producto clave OTX-TKI, presentando tres sesiones distintas:
1. El Dr. Carl J. Danzig presentará sobre la progresión de OTX-TKI de la Fase 1 a la Fase 3, discutiendo los ensayos SOL-1 y SOL-R para la AMD neovascular a las 2:30 PM ET.
2. El Dr. Mark R. Barakat compartirá los resultados de la Fase 1 del implante intravítreo de axitinib (OTX-TKI) para tratar la retinopatía diabética no proliferativa a las 5:20 PM ET.
3. El Dr. Justis P. Ehlers presentará los hallazgos del análisis volumétrico del fluido macular del Ensayo Clínico HELIOS a las 5:25 PM ET, examinando el impacto de un único implante intravítreo de axitinib en el tratamiento de la retinopatía diabética.
Ocular Therapeutix (NASDAQ: OCUL)는 2025년 2월 8일에 열릴 혈관형성, 삼출 및 퇴행성 증상 가상 회의에 대해 여러 발표가 예정되어 있다고 발표했습니다. 발표는 그들의 주요 제품인 OTX-TKI에 초점을 맞추며, 세 가지 별도의 세션이 진행됩니다:
1. Carl J. Danzig 박사가 OTX-TKI가 1상에서 3상으로 진행되는 과정에 대해 발표하며, 2:30 PM ET에 망막신생혈관 AMD을 위한 SOL-1 및 SOL-R 시험을 논의합니다.
2. Mark R. Barakat 박사가 비증식성 당뇨병성 망막병증 치료를 위한 intravitreal axitinib 임플란트(OTX-TKI)의 1상 결과를 5:20 PM ET에 공유합니다.
3. Justis P. Ehlers 박사가 HELIOS 임상 시험에서의 체적 황반액 분석 결과를 5:25 PM ET에 발표하며, 당뇨병성 망막병증 치료에서 단일 axitinib intravitreal 임플란트의 영향을 살펴봅니다.
Ocular Therapeutix (NASDAQ: OCUL) a annoncé plusieurs présentations prévues pour la réunion virtuelle sur l'Angiogénèse, l'Exsudation et la Dégénérescence 2025 le 8 février 2025. Les présentations se concentreront sur leur produit phare OTX-TKI, comprenant trois sessions distinctes :
1. Le Dr Carl J. Danzig présentera l'évolution de OTX-TKI de la phase 1 à la phase 3, en discutant des essais SOL-1 et SOL-R pour l'AMD néovasculaire à 14h30 ET.
2. Le Dr Mark R. Barakat partagera les résultats de la phase 1 de l'implant intravitréen d'axitinib (OTX-TKI) pour le traitement de la rétinopathie diabétique non proliférante à 17h20 ET.
3. Le Dr Justis P. Ehlers présentera les résultats de l'analyse volumétrique du fluide maculaire de l'essai clinique HELIOS à 17h25 ET, examinant l'impact d'un implant intravitréen d'axitinib unique dans le traitement de la rétinopathie diabétique.
Ocular Therapeutix (NASDAQ: OCUL) hat mehrere Präsentationen für das virtuelle Treffen zur Angiogenese, Exsudation und Degeneration 2025 am 8. Februar 2025 angekündigt. Die Präsentationen werden sich auf ihr Hauptprodukt OTX-TKI konzentrieren und bestehen aus drei unterschiedlichen Sitzungen:
1. Dr. Carl J. Danzig wird die Fortschritte von OTX-TKI von Phase 1 bis Phase 3 präsentieren und die SOL-1 und SOL-R Studien zur neovaskulären AMD um 14:30 Uhr ET diskutieren.
2. Dr. Mark R. Barakat wird um 17:20 Uhr ET die Ergebnisse der Phase 1 des intravitrealen Axitinib-Implantats (OTX-TKI) zur Behandlung der nicht-proliferativen diabetischen Retinopathie vorstellen.
3. Dr. Justis P. Ehlers wird um 17:25 Uhr ET die Ergebnisse der volumenmetrischen Analyse des makulären Flusses aus der HELIOS-Studie präsentieren und die Auswirkungen eines einzelnen intravitrealen Axitinib-Implantats auf die Behandlung von diabetischer Retinopathie untersuchen.
- None.
- None.
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025.
Presentation Details:
- OTX-TKI From Phase 1 to Phase 3: SOL-1 and SOL-R Trials for Neovascular AMD
Session: V: Imaging and Emerging Therapies for Exudative AMD
Presentation Time: 2:30 PM ET
Presenter: Carl J. Danzig, MD
- Phase 1 Results from Intravitreal Axitinib Implant (OTX-TKI) for the Treatment of Non-Proliferative Diabetic Retinopathy
Session: VII: Diabetic Retinopathy and Retinal Vascular Diseases
Presentation Time: 5:20 PM ET
Presenter: Mark R. Barakat, MD
- Volumetric Macular Fluid Analysis of the Impact of a Single Axitinib Intravitreal Implant (OTX-TKI) from the HELIOS Clinical Trial for Diabetic Retinopathy
Session: VII: Diabetic Retinopathy and Retinal Vascular Diseases
Presentation Time: 5:25 PM ET
Presenter: Justis P. Ehlers, MD
Exact presentation times are subject to change. Expected presentation times can be found on the Program section of the Angiogenesis, Exudation, and Degeneration 2025 conference website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What clinical trials will be presented for OCUL's OTX-TKI at the Angiogenesis 2025 meeting?
When and where will Ocular Therapeutix present its OTX-TKI research in February 2025?
What medical conditions is OCUL's OTX-TKI being developed to treat?
Who are the key presenters for OCUL's research at the Angiogenesis 2025 meeting?
What are the presentation times for OCUL's research at the Angiogenesis 2025 meeting?
